Unibest

Pharmaceutical intermediates

Iguratimod Intermediates

3 pharmaceutical intermediates for Iguratimod. Indication: Rheumatoid arthritis.

提交项目All intermediates

About Iguratimod

Originator
Jiangsu Simcere Pharmaceutical Co., Ltd.
Indication
Rheumatoid arthritis
Approved Date
04/21/2008

Available intermediates

3 intermediates currently listed for Iguratimod. Request specifications, documentation or a quotation for any item below.

Iguratimod intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
N-(4-glycyl-5-methoxy-2-phenoxyphenyl)methanesulfonamide hydrochloride149436-41-9//
N-(5-Methoxy-2-phenoxyphenyl)methanesulfonamide123664-84-6//
N-[4-[(Formylamino)acetyl] -5-hydroxy-2- phenoxyphenyl]methanesulfonamide149457-03-4//

Other programs under I

Ibrutinib/ Zanubrutinib ImatinibImeglimin hydrochlorideIndacaterol MaleateInfigratinibIpatacopan HydrochlorideIpragliflozinIrinotecan

Building toward Iguratimod?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →